##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 147 No. 4546 (2017)

Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload

  • Axel Rüfer
  • Christine Bapst
  • Rudolf Benz
  • Jens Bremerich
  • Nathan Cantoni
  • Laura Infanti
  • Kaveh Samii
  • Mathias Schmid
  • Jean-Paul Vallée
Cite this as:
Swiss Med Wkly. 2017;147:w14550
Published
08.11.2017

Summary

Hyperferritinaemia is a frequent clinical problem. Elevated serum ferritin levels can be detected in different genetic and acquired diseases and can occur with or without anaemia. It is therefore important to determine whether hyperferritinaemia is due to iron overload or due to a secondary cause. The main causes of iron overload are intestinal iron hyperabsorption disorders and transfusion-dependent disorders. Iron homeostasis and iron overload are quantified by different diagnostic approaches. The evaluation of serum ferritin and transferrin saturation is the first diagnostic step to identify the cause of hyperferritinaemia. The assessment of liver iron concentration by liver biopsy or magnetic resonance imaging (MRI) may guide the further diagnostic and therapeutic workup. Liver biopsy is invasive and poorly accepted by patients and should only be carried out in selected patients with hereditary haemochromatosis. As a non-invasive approach, MRI is considered the standard method to diagnose and to monitor both hepatic iron overload and the effectiveness of iron chelation therapy in many clinical conditions such as thalassaemia and myelodysplastic syndromes. Accurate evaluation and monitoring of iron overload has major implications regarding adherence, quality of life and prognosis. There are different technical MRI approaches to measuring the liver iron content. Of these, T2 and T2* relaxometry are considered the standard of care. MRI with cardiac T2* mapping is also suitable for the assessment of cardiac iron. Currently there is no consensus which technique should be preferred. The choice depends on local availability and patient population. However, it is important to use the same MRI technique in subsequent visits in the same patient to get comparable results. Signal intensity ratio may be a good adjunct to R2 and R2* methods as it allows easy visual estimation of the liver iron concentration. In this review a group of Swiss haematologists and radiologists give an overview of different conditions leading to primary or secondary iron overload and on diagnostic methods to assess hyperferritinaemia with a focus on the role of liver MRI. They summarise the standard practice in Switzerland on the use of liver iron concentration MRI as well as disease-specific guideline recommendations.

References

  1. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–95. doi:.https://doi.org/10.1056/NEJM199912233412607
  2. Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging. 2014;40(5):1003–21. doi:.https://doi.org/10.1002/jmri.24584
  3. Wood JC. Estimating tissue iron burden: current status and future prospects. Br J Haematol. 2015;170(1):15–28. doi:.https://doi.org/10.1111/bjh.13374
  4. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348–59. doi:.https://doi.org/10.1056/NEJMra1004967
  5. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850(1 COOLEY'S ANEM):191–201. doi:.https://doi.org/10.1111/j.1749-6632.1998.tb10475.x
  6. Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84(1):29–33. doi:.https://doi.org/10.1002/ajh.21317
  7. Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1–10. doi:.https://doi.org/10.1007/s00277-010-1091-1
  8. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277–87. doi:.https://doi.org/10.1016/j.beha.2004.10.003
  9. Quinn CT, St Pierre TG. MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer. 2016;63(5):773–80. doi:.https://doi.org/10.1002/pbc.25882
  10. Ruefer A, Howell JP, Lange AP, et al. Hyperferritinämie und Eisenmangel – eine aussergewöhnliche Liaison. Schweiz Med Forum. 2011;11:87–8. Article in German.
  11. Camaschella C, Poggiali E. Towards explaining “unexplained hyperferritinemia”. Haematologica. 2009;94(3):307–9. doi:.https://doi.org/10.3324/haematol.2008.005405
  12. Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol. 2011;55(2):453–8. doi:.https://doi.org/10.1016/j.jhep.2011.02.010
  13. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS ; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(1):328–43. doi:.https://doi.org/10.1002/hep.24330
  14. Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G ; German hematology societies (GPOH and DGHO). S2-Leitlinie zur Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia]. Klin Padiatr. 2010;222(6):399–406. Article in German. doi:.https://doi.org/10.1055/s-0030-1265178
  15. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–603. doi:.https://doi.org/10.1200/JCO.2005.01.7038
  16. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115(2):239–52. doi:.https://doi.org/10.1046/j.1365-2141.2001.03195.x
  17. Neukirchen J, Schoonen WM, Aul C, et al. Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Dusseldorf 1996-2005. ASH Annual Meeting Abstracts 2009;114:1774
  18. Weatherall DJ. Hemoglobinopathies worldwide: present and future. Curr Mol Med. 2008;8(7):592–9. doi:.https://doi.org/10.2174/156652408786241375
  19. Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). Nicosia, Cyprus: Thalassaemia International Federation; 2014
  20. Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013;87(3):183–90.
  21. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873–81. doi:.https://doi.org/10.1182/blood-2014-03-563221
  22. Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. Drugs. 2011;71(2):155–77. doi:.https://doi.org/10.2165/11585280-000000000-00000
  23. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–93.
  24. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331(9):574–8. doi:.https://doi.org/10.1056/NEJM199409013310903
  25. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855–61. doi:.https://doi.org/10.1182/blood-2004-01-0177
  26. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739–61.
  27. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6(1):24–9. doi:.https://doi.org/10.1002/hep.1840060106
  28. Angelucci E, Giovagnoni A, Valeri G, Paci E, Ripalti M, Muretto P, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood. 1997;90(12):4736–42.
  29. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138(5):587–93. doi:.https://doi.org/10.1111/j.1365-2141.2007.06695.x
  30. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93(9):1385–8. doi:.https://doi.org/10.3324/haematol.12759
  31. Wood JC. Impact of iron assessment by MRI. Hematology (Am Soc Hematol Educ Program). 2011;2011(1):443–50. doi:.https://doi.org/10.1182/asheducation-2011.1.443
  32. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–9. doi:.https://doi.org/10.1053/euhj.2001.2822
  33. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–8. doi:.https://doi.org/10.1161/CIRCULATIONAHA.109.874487
  34. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005;1054(1):373–8. doi:.https://doi.org/10.1196/annals.1345.045
  35. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327–31. doi:.https://doi.org/10.1056/NEJM200008033430503
  36. Wood JC. Guidelines for quantifying iron overload. Hematology (Am Soc Hematol Educ Program). 2014;2014(1):210–5. doi:.https://doi.org/10.1182/asheducation-2014.1.210
  37. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115(1-2):106–8. doi:.https://doi.org/10.1159/000089475
  38. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology (Am Soc Hematol Educ Program). 2009;2009(1):215–21. doi:.https://doi.org/10.1182/asheducation-2009.1.215
  39. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3–22. doi:.https://doi.org/10.1016/j.jhep.2010.03.001
  40. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–69. doi:.https://doi.org/10.1182/blood-2012-05-370098
  41. Angelucci E, Baronciani D, Lucarelli G, Baldassarri M, Galimberti M, Giardini C, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89(4):757–61. doi:.https://doi.org/10.1111/j.1365-2141.1995.tb08412.x
  42. Villeneuve JP, Bilodeau M, Lepage R, Côté J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol. 1996;25(2):172–7. doi:.https://doi.org/10.1016/S0168-8278(96)80070-5
  43. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. Clin Chem. 1999;45(3):340–6.
  44. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460–5. doi:.https://doi.org/10.1182/blood-2004-10-3982
  45. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23(1):1–25. doi:.https://doi.org/10.1016/j.mri.2004.10.001
  46. Plewes DB, Kucharczyk W. Physics of MRI: a primer. J Magn Reson Imaging. 2012;35(5):1038–54. doi:.https://doi.org/10.1002/jmri.23642
  47. Currie S, Hoggard N, Craven IJ, Hadjivassiliou M, Wilkinson ID. Understanding MRI: basic MR physics for physicians. Postgrad Med J. 2013;89(1050):209–23. doi:.https://doi.org/10.1136/postgradmedj-2012-131342
  48. St Pierre TG, Clark PR, Chua-Anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci. 2005;1054:379–85. doi:.https://doi.org/10.1196/annals.1345.046
  49. Wood JC. Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am. 2014;28(4):747–64, vii. doi:.https://doi.org/10.1016/j.hoc.2014.04.002
  50. Runge JH, Akkerman EM, Troelstra MA, Nederveen AJ, Beuers U, Stoker J. Comparison of clinical MRI liver iron content measurements using signal intensity ratios, R 2 and R 2. Abdom Radiol (NY). 2016;41(11):2123–31. doi:.https://doi.org/10.1007/s00261-016-0831-7
  51. Gandon Y, Olivié D, Guyader D, Aubé C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363(9406):357–62. doi:.https://doi.org/10.1016/S0140-6736(04)15436-6
  52. St Pierre TG, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S, et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magn Reson Med. 2014;71(6):2215–23. doi:.https://doi.org/10.1002/mrm.24854
  53. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld EJ. Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. Magn Reson Imaging. 2015;33(6):761–7. doi:.https://doi.org/10.1016/j.mri.2015.02.016
  54. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123(14):1519–28. doi:.https://doi.org/10.1161/CIRCULATIONAHA.110.007641
  55. Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853–5. doi:.https://doi.org/10.1182/blood-2008-12-191643
  56. Alam MH, Auger D, McGill LA, Smith GC, He T, Izgi C, et al. Comparison of 3 T and 1.5 T for T2* magnetic resonance of tissue iron. J Cardiovasc Magn Reson. 2016;18(1):40. doi:.https://doi.org/10.1186/s12968-016-0259-9
  57. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld E. R2 and R2* are equally effective in evaluating chronic response to iron chelation. Am J Hematol. 2014;89(5):505–8. doi:.https://doi.org/10.1002/ajh.23673
  58. Garbowski MW, Carpenter JP, Smith G, Roughton M, Alam MH, He T, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):40. doi:.https://doi.org/10.1186/1532-429X-16-40
  59. Gandon Y, Guyader D, Heautot JF, Reda MI, Yaouanq J, Buhé T, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology. 1994;193(2):533–8. doi:.https://doi.org/10.1148/radiology.193.2.7972774
  60. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9(9):1187–94. doi:.https://doi.org/10.1038/nm920
  61. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973–8. doi:.https://doi.org/10.1182/blood-2008-04-148767
  62. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10(1):42. doi:.https://doi.org/10.1186/1532-429X-10-42
  63. Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, et al.; CORDELIA study investigators. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. Am J Hematol. 2015;90(2):91–6. doi:.https://doi.org/10.1002/ajh.23876
  64. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114(19):4021–6. doi:.https://doi.org/10.1182/blood-2009-06-225615
  65. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–73. doi:.https://doi.org/10.1056/NEJM199409013310902
  66. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971–7. doi:.https://doi.org/10.1046/j.1365-2141.2000.02298.x
  67. Roy NB, Myerson S, Schuh AH, Bignell P, Patel R, Wainscoat JS, et al. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes. Br J Haematol. 2011;154(4):521–4. doi:.https://doi.org/10.1111/j.1365-2141.2011.08749.x
  68. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842–8. doi:.https://doi.org/10.3324/haematol.2011.049957
  69. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2011;118(4):884–93. doi:.https://doi.org/10.1182/blood-2010-11-316646
  70. Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, et al.; EPIC study investigators. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143–50. doi:.https://doi.org/10.1016/j.leukres.2010.03.009
  71. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5):741–52. doi:.https://doi.org/10.3324/haematol.12413
  72. Vichinsky E, Levine L. Standards of care guidelines for thalassemia. Oakland: Children's Hospital and Research Center; 2012
  73. Musallam KM, Angastiniotis M, Eleftheriou A, Porter JB. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol. 2013;130(2):64–73. doi:.https://doi.org/10.1159/000345734
  74. Bennett JM ; MDS Foundation’s Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83(11):858–61. doi:.https://doi.org/10.1002/ajh.21269
  75. National Comprehensive Cancer Network. Myelodysplastic Syndromes. NCCN Clinical Practice Guidelines in Oncology; 2017
  76. Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, et al. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009;7(Suppl 9):S1–16. doi:.https://doi.org/10.6004/jnccn.2009.0082